Reach Us +441414719275
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Influence of Hyperlipidemia on Pharmacokinetics of Clarithromycin in Wistar Rats

To investigate impact of hyperlipidemia on clarithromycin pharmacokinetics in Wistar rats, hyperlipidemia was successfully induced by providing high fat diet (rich of cholesterol) for 6-8 weeks. Pharmacokinetic parameters of clarithromycin in induced hyperlipidemia and control group (non-hyperlipidemia) were determined in rats after oral (10, 20, and 100 mg/kg) single administration of clarithromycin. Group allocation for in-vivo study (n=6) as follows: G1: Vehicle control, G2-G4: Non-hyperlipidemic rats treated with clarithromycin, G5-G7: hyperlipidemic rats treated with clarithromycin. For In-vitro study (n=4): G8: Nonhyperlipidemic rats pooled liver homogenate, G9: Hyperlipidemic rat pooled liver homogenate for investigation of clarithromycin metabolism. For biliary excretion studies (n=4): G10: nonhyperlipidemic rats treated with clarithromycin and G11: Hyperlipidemic rats treated with clarithromycin. The area under the plasma concentration–time curve (AUC0–∞) and the peak plasma concentration (Cmax) of clarithromycin (non-hyperlipidemic group) was 1.77 ± 0.33 μg. h/mL and 0.47 ± 0.06 μg/mL for 10 mg/kg; 5.63 ± 1.51 μg. h/mL and 1.21 ± 0.11 μg/mL for 20 mg/kg; 58.97 ± 12.74 μg. h/mL and 12.48 ± 3.8 μg/mL for 100 mg/kg, respectively. In hyperlipidemic group the AUC0–∞ and Cmax of clarithromycin was 3.47 ± 0.82 μg.h/mL and 0.84 ± 0.09 ug/mL for 10 mg/kg; 12.21 ± 2.83 μg.h/mL and 2 ± 0.24 μg/mL for 20 mg/kg; 141.88 ± 54.03 μg.h/mL and 20.57 ± 7.6 μg/mL for 100 mg/kg, respectively. Over all exposure was significantly increased in hyperlipidemic groups at across the tested doses. The percentage remaining of clarithromycin in hyperlipidemic rat’s liver homogenates and biliary excretion was significantly (P<0.05) high as compared with non-hyperlipidemic rats. The % dose excretion of clarithromycin in urine was lower as compared with bile in hyperlipidemic rats. Conclude that the clarithromycin was considerably affected by hyperlipidemia. The enhanced area under the curve of clarithromycin in hyperlipidemic rats might be mainly due to inhibition of the CYP mediated metabolism in the liver by hyperlipidemia which was reproduced in bile and urine.


Author(s): K. Prasanna Kumar and Y. Narsimha Reddy

Abstract | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Chemical Abstracts Service (CAS)
  • Google Scholar
  • Sherpa Romeo
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Open Academic Journals Index (OAJI)
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Scientific Journal Impact Factor
  • International Committee of Medical Journal Editors (ICMJE)
  • Secret Search Engine Labs